<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351284</url>
  </required_header>
  <id_info>
    <org_study_id>20/15</org_study_id>
    <nct_id>NCT02351284</nct_id>
  </id_info>
  <brief_title>Impact of Hypovitaminosis D on Bone Disease in HIV Infected Patients</brief_title>
  <acronym>PuraVIHta</acronym>
  <official_title>Impact of Hypovitaminosis D in Metabolic Disturbances and Bone Metabolism, and Changes in Patients Receiving Vitamin D Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jose L. Casado</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociacion para el Estudio de las Enfermedades Infecciosas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the prevalence of hypovitaminosis D in HIV infected patients, and the
      consequences on secondary hyperparathyroidism, and bone mineral density (BMD). Also, to
      establish the improvement in vitamin D status, parathyroid hormone (PTH) and BMD, in case of
      receiving vitamin D supplementation, during a follow up period of at least 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study deals with the impact of vitamin D on metabolism and bone health in HIV infected
      patients. To answer the questions about the importance of this hormone in this population, we
      designed a cohort study about the prevalence of vitamin D deficiency (measured as
      25-hydroxy-vitamin D), classifying it in severe deficiency (&lt;10 ng/ml), deficiency (&lt; 20
      ng/ml), or insufficiency (&lt; 30 ng/ml), the relationship with secondary hyperparathyroidism
      (PTH &gt; 65 pg/ml), and related BMD by dual X-ray absorptiometry (DXA). These results will be
      adjusted by baseline factors, such as age, gender, body mass index (BMI), hepatitis C virus
      (HCV) coinfection, risk practice for HIV infection, CD4+ count, antiretroviral therapy, and
      HIV RNA level.

      In patients receiving vitamin D supplementation according to clinical decision, it will be
      evaluated the changes in percentage of hypovitaminosis D and/or secondary
      hyperparathyroidism, and the effect on BMD. Bone biomarkers will be collected to determine
      the impact of changes secondary to vitamin D improvement in the bone evolution.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Prevalence of osteopenia/osteoporosis and secondary hyperparathyroidism in HIV infected patients according to vitamin D strata</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of patients with high PTH and reduced BMD in each vitamin D strata (&lt; 10 ng/ml, 10-20 ng/ml, 20-30 ng/ml, &gt; 30 ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vitamin D levels secondary to seasonality</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in 25-hydroxy vitamin D according to season</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of supplementation in reducing secondary hyperparathyroidism and osteopenia/osteoporosis</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in PTH and BMD (% of patients having secondary hyperparathyroidism and osteopenia/osteoporosis) after receiving vitamin D supplementation according to clinical decision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of vitamin D levels (25OHD) in reducing phosphaturia levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Improvement in phosphaturia levels (elemental urine) according to vitamin D strata and/or supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between values of bone biomarkers (osteocalcin, beta-crosslaps, alkaline phosphatase, P1NP) and rates of osteopenia/osteoporosis</measure>
    <time_frame>48 weeks</time_frame>
    <description>To establish baseline values and relationship of bone biomarkers with bone mineral density status, adjusted by vitamin D strata</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypovitaminosis D</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement</intervention_name>
    <description>Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients in follow up
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV older than 18 years

        Exclusion Criteria:

          -  Chronic kidney disease stage 4 and 5 (creatinine clearance &lt; 30 ml/min)

          -  Pregnancy

          -  Uso of corticosteroid therapy, or requiring anti-resorptive treatment

          -  Prolonged hospitalization or internment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Ba√±on, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramon y Cajal Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose L Casado, MD</last_name>
    <phone>34913368672</phone>
    <email>jcasado.hrc@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asociacion para el Estudio de las Enfermedades Infecciosas</investigator_affiliation>
    <investigator_full_name>Jose L. Casado</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>HIV, vitamin D, osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

